Teva Comments On Sandoz Implications Amid Strategic Review
Israeli Firm Has Ruled Itself Out Of Merging With Novartis Unit
Executive Summary
Teva CEO Kåre Schultz has weighed in on Novartis’ plans to conduct a strategic review for its Sandoz unit, while also airing frustrations over continued delays for complex products in the US.
You may also be interested in...
Sandoz Does Not Budge On 2022 Expectations Despite Positive Start
A weak base for the prior year and several one-time items allowed Sandoz to post positive financial results for the first quarter of 2022, including a 26% jump in the company’s core operating profit. Electing not to upgrade its expectations for Sandoz this year, Novartis will continue to monitor the business amid an ongoing strategic review.
Generics Firms Resign Themselves To A Merger Drought As Regulators Tighten Up
Unable to predict which divestures will be required by the EU or the US FTC, firms will instead look to private equity, their organic pipeline, or partnerships for growth, CEOs forecast on the last day of the generic trade association’s annual meeting.
Generic Firms Resign Themselves To A Merger Drought As Regulators Tighten Up
Unable to predict which divestures will be required by the EU or the US FTC, firms will instead look to private equity, their organic pipeline, or partnerships for growth, CEOs forecast on the last day of the generic trade association’s annual meeting.